Novartis Confidential Page 2
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Table of contents
Table of contents ................................................................................................................. 2
List of tables ........................................................................................................................ 5
List of figures ...................................................................................................................... 6
List of abbreviations ............................................................................................................ 7
Glossary  of terms ............................................................................................................... 10
Protocol Amendment 3 (08
-Sep-2021)..................................................................................... 12
Protocol Amendment 2 (05- Apr-2021) .................................................................................... 13
Local Protocol Amendment 1 (for Canada onl y, 30 -Oct-
2019)........................................ 15
Protocol Amendment 1 (02
-Oct-2019).............................................................................. 16
Protocol summary .............................................................................................................. 18
1Introduction ....................................................................................................................... 21
1.1 Background ............................................................................................................ 21
1.2 Purpose .................................................................................................................. 21
2Objectives and endpoints ................................................................................................... 22
3Study  design ................................ ................................ ................................ ...................... 23
4Rationale ............................................................................................................................ 25
4.1 Rationale for stud y design ..................................................................................... 25
4.1.1 Rationale for choice of background therap y
......................................... 25
4.2
Rationale for dose/regimen and duration of treatment .......................................... 26
4.3 Rationale for choice of control drug s (comparator/placebo) or combination 
drugs ...................................................................................................................... 26
26
4.5 Risks and benefits .................................................................................................. 26
4.6 Rationale for Public Health Emergency  mitigation procedures
............................ 29
5Population .......................................................................................................................... 29
5.1 Inclusion criteria .................................................................................................... 29
5.2 Exclusion criteria ................................................................................................... 30
6Treatment ........................................................................................................................... 32
6.1 Study  treatment ...................................................................................................... 32
6.1.1 Investigational and control drugs .......................................................... 32
6.1.2 Additional study  treatments .................................................................. 33
6.1.3 Treatment arms/group ........................................................................... 33
6.1.4 Treatment duration ................................................................................ 33
6.2 Other treatment(s) .................................................................................................. 33
6.2.1 Concomitant therap y
............................................................................. 33
6.2.2
Prohibited medication ........................................................................... 34

Novartis Confidential Page 3
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
35
6.3 Subject numbering, treatment assignment, randomization .................................... 35
6.3.1 Subject numbering ................................................................................ 35
6.3.2 Treatment assignment, randomization .................................................. 35
6.4 Treatment blinding ................................................................................................. 35
6.5
Dose escalation and dose modification.................................................................. 35
6.6 Additional treatment guidance ............................................................................... 35
6.6.1 Treatment compliance ........................................................................... 35
6.6.2 Emergency  breaking of assigned treatment code .................................. 36
6.7 Preparation and dispensation ................................................................................. 36
6.7.1 Handling of study
 treatment and additional treatment.......................... 36
6.7.2 Instruction for prescribing and taking stud y treatment ......................... 37
7Informed consent procedures ............................................................................................ 37
8
Visit schedule and assessments ......................................................................................... 38
8.1 Screening ............................................................................................................... 45
8.1.1 Information to be collected on screening failures ................................. 45
8.2
Subject demographics/other baseline characteristics............................................. 45
8.3 Efficacy .................................................................................................................. 45
8.3.1 eDiary  assessments ................................................................................ 46
49
8.3.3 Appropriateness of efficacy  assessments .............................................. 49
8.4 Safety /Tolerability ................................................................................................. 49
8.4.1 Laboratory  evaluations .......................................................................... 50
8.4.2 Electrocardiogram (ECG) ..................................................................... 51
8.4.3 Pregnancy .............................................................................................. 52
8.4.4 Other safety
 evaluations ........................................................................ 52
8.4.5 Appropriateness of safety  measurements .............................................. 52
.52
52
53
9Study  discontinuation and completion .............................................................................. 53
9.1 Discontinuation ...................................................................................................... 53
9.1.1 Discontinuation of study  treatment ....................................................... 53
9.1.2 Withdrawal of informed consent ........................................................... 55
9.1.3 Lost to follow -
up................................................................................... 55
9.1.4 Early study termination by the sponsor ................................................. 55
9.2 Study  completion and post -study  treatment .......................................................... 56

Novartis Confidential Page 4
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
10Safety  monitoring and reporting ................................ ................................ ........................ 56
10.1 Definition of adverse events and reporting requirements ...................................... 56
10.1.1 Adverse events ...................................................................................... 56
10.1.2 Serious adverse events .......................................................................... 58
10.1.3 SAE reporting
........................................................................................ 59
10.1.4 Pregnancy  reporting .............................................................................. 59
10.1.5 Reporting of stud y treatment errors including misuse/abuse ................ 60
10.2 Additional Safety  Monitoring ................................................................................ 60
10.2.1 Liver safety  monitoring ......................................................................... 60
10.2.2 Renal safet y monitoring ................................ ................................ ........ 61
10.2.3 Data Monitoring Committee ................................................................. 62
10.2.4 Steering Committee ............................................................................... 62
11Data Collection and Database management ...................................................................... 62
11.1
Data collection....................................................................................................... 62
11.2 Database management and quality  control ................................ ............................ 62
11.3 Site monitoring ...................................................................................................... 63
12Data analy sis and statistical methods ................................ ................................ ................ 64
12.1 Analy sis sets .......................................................................................................... 64
12.2
Subject demographics and other baseline characteristics...................................... 64
12.3 Treatments ............................................................................................................. 65
12.4 Analy sis of the primary  endpoint(s) ...................................................................... 65
12.4.1 Definition of primary  endpoint(s) ......................................................... 65
12.4.2 Statistical model, hy pothesis, and method of analysis.......................... 66
12.4.3 Handling of missing values/censoring/discontinuations ....................... 66
12.4.4 Sensitivity  and Supportive anal yses...................................................... 66
12.5 Analy sis of secondary  endpoints ........................................................................... 67
12.5.1 Efficacy  and/or Pharmacody namic endpoint(s) .................................... 67
12.5.2 Safety  endpoints .................................................................................... 67
67
68
12.8
Sample size calculation.......................................................................................... 69
12.8.1 Primary  endpoint(s) ............................................................................... 69
12.8.2 Secondary  endpoint(s) ........................................................................... 69
13Ethical considerations and administrative procedures ...................................................... 69
13.1 Regulatory
 and ethical compliance ........................................................................ 69
13.2 Responsibilities of the investigator and IRB/ IEC.................................................. 69
13.3 Publication of study  protocol and results ............................................................... 69

Novartis Confidential Page 5
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
13.4 Quality  Control and Quality  Assurance ................................ ................................ .70
14Protocol adherence ............................................................................................................ 70
14.1 Protocol Amendmen ts........................................................................................... 70
15References ......................................................................................................................... 71
16Appendices ........................................................................................................................ 73
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs ......................... 73
16.2 Appendix 2: L iver event and Laboratory  trigger Definitions and Follow
-up 
Requirements ......................................................................................................... 74
16.3
Appendix 3: Specific Renal Alert Criteria and Actions and Event Follow- up...... 77
16.4 Appendix 4: Prohibited medications ..................................................................... 79
80
85
List of tables
Table 2
-1 Objectives and related endpoints .......................................................... 22
Table 6
-1 Investigational drug ............................................................................... 32
Table 6
-2 Prohibited medication ........................................................................... 34
Table 8
-1 Assessment Schedule, Treatment period and Follow- up peri od........... 40
Table 8-2 Assessment Schedule, Observational period ......................................... 43
Table 8
-3 UPDD .................................................................................................... 46
Table 8
-4 Hives Severit y Score ............................................................................. 47
Table 8
-5 Itch Severit y Score ............................................................................... 47
47
47
49
Table 8
-9 Physical Assessments ........................................................................... 50
Table 8
-10 Laboratory assessments ........................................................................ 51
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse ................................ ................................ ......................... 60
69
Table 16-1 Liver Event and Laboratory  Trigger Definitions ................................ ..74
Table 16-2 Follow Up Requirements for L iver Events and Laboratory  Triggers ...74
Table 16-3 Specific renal alert criteria and actions ................................................. 77
Table 16-4 Renal event follow -up ........................................................................... 78
Table 16
-5 Moderate and strong inhibitors of CYP3A4 ......................................... 79
Table 16-6 Moderate and st rong inducers of CYP3A4 ................................ ........... 79
85

Novartis Confidential Page 6
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
85
List of figures
Figure 3 -1 Study  design .......................................................................................... 24
Figure 3 -
2 Patient flow from CL OU064A2201 ...................................................... 25

Novartis Confidential Page 7
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
List of abbreviations
AE Adverse Event
Alb Albumin
ALP Alkaline Phosphatase
ALT Alanine Aminotransferase
APTT Activated Partial Thromboplastin Time
AST Aspartate Aminotransferase
AUC Area Under the Curve
AV block Atrioventricular block 
BCR B Cell Receptor
BCRP Breast cancer resistance protein
b.i.d. bis in die / twice a day
BP Blood Pressure
BTK Bruton’s T yrosine Kinase
BTKi Bruton’s T yrosine Kinase Inhibitor
BUN Blood Urea Nitrogen
CK Creatine Kinase
CMO&PS Chief Medical Office and Patient Safety
CO Countr y Organization
COA Clinical Outcomes Assessment
COVID -19 Coro navirus Disease of 2019
CRA Clinical Research Associate
CRF Case Report/Record Form (paper or electronic)
CRO Contract Research Organization
CRP C-Reactive Protein
CSR Clinical study report
CSU Chronic Spontaneous Urticaria
CU Chronic Urticaria
CYP Cytochrome P
DBP Diastolic Blood Pressure
DDE Direct Data Entry
DDI Drug -Drug Interaction
DIN Drug -Induced Nephrotoxicity
DMC Data Monitoring Committee
DNA Deoxyribonucleic acid
ECG Electrocardiogram
EDC Electronic Data Capture
eGFR Estimated Glomerular Filtration Rate
EMA European Medicines Agency
eSource Electronic Source 

Novartis Confidential Page 8
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
EU European Union
FAS Full Analysis Set
FcεR Fc epsilon receptor
FcγR Fc gamma receptor
FSH Follicle -stimulating hormone
GCP Good Clinical Practice
GCS Global Clinical Supply
GGT Gamma -glutam yl transferase
h hour
HCP Health Care Professional
HDL High-Density Lipoprotein
hERG human Ether -à-go-go Related Gene
HIV Human immunodeficiency Virus
HRQoL Health -Related Quality of Life
HSS7 Weekly Hives Severity Score
IB Investigator’s Brochure
ICF Informed Consent Form
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use
IEC Independent Ethics Committee
Ig Immunoglobulin
IMP Investigational Medical Product
IN Investigator Notification
INR International Normalized Ratio
IRB Institutional Review Board
IRT Interactive Response Technology
ISS7 Weekly Itch Severity Score
IUD Intrauterine device
IUS Intrauterine system
i.v. intravenous
LDH lactate dehydrogenase
LDL Low-Density Lipoprotein
LFT Liver function test 
LLOQ lower limit of quantification
MAD Multiple Ascending Dose
MCH Mean Corpuscular Hemoglobin
MCHC Mean Corpuscular Hemoglobin Concentration
MCV Mean Corpuscular Volume
MedDRA Medical dictionary for regulatory activities 
mg mi lligram (s)
mL mi lliliter(s)

Novartis Confidential Page 9
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
MRI Magnetic Resonance Imaging
ng Nanogram(s)
NOAC Novel Oral Anti -Coagulant
NOAEL No-Observed Adverse Event Level
NSAID Nonsteroidal Anti -Inflammatory Drug
PCR Protein -creatinine ratio
PD Pharmacodynamic(s)
P-gp Permeability glycoprotein, P -glycoprotein
PT prothrombin time
q.d. quaque die / once a day
QMS Quality Management System
QoL Quality of Life
QTcF QT interval corrected by Fridericia’s formula
RBC Red Blood Cell(s)
RNA Ribonucleic Acid
SAD Single Ascending Dose
SAE Serious Adverse Event
SBP Systolic Blood Pressure
SC Steering Committee
sCr Serum Creatinine
SD Standard Deviation
SmPC Summary  of Product Characteristics
SMQ Standardized MedDRA Query
SOP Standard Operating Procedure
SPT Skin Prick Test
SUSAR Suspected Unexpected Serious Adverse Reactions
TBL Total Bilirubin
UAS Urticaria Activity Score
ULN Upper Limit of Normal
ULOQ Upper Limit Of Quantification
UPDD Urticaria Patient Daily Diar y
US United States (of America)
UTI Urinar y Tract Infection
WBC White Blood Cell(s)
WHO World Health Organization 
WoCBP Women of Child -Bearing Potential
XLA X-linked Agammaglobulinemia

Novartis Confidential Page 10
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Glossary  of terms
Additional treatment Medicinal products that may be used during the clinical trial as described 
in the protocol, but not as an investigational medicinal product (e.g. any 
background therapy ).
Assessment A procedure used to generate data required by the study
Biologic Samples A biological specimen including, for example, blood (plasma, serum), 
saliva, tissue, urine, stool, etc. taken from a study subject 
Cohort A specific group of subjects fulfilling cert ain criteria and generally treated 
at the same time
Control drug A study drug (active or placebo) used as a comparator to reduce 
assessment bias, preserve blinding of investigational drug, assess 
internal study validity, and/or evaluate comparative effect s of the 
investigational drug
Dosage Dose of the study treatment given to the subject in a time unit (e.g. 100 
mg once a day, 75 mg twice a day)
Electronic Data Capture 
(EDC)Electronic data capture (EDC) is the electronic acquisition of clinical 
study data using data collection s ystems, such as Web-based 
applications, interactive voice response s ystems and clinical laboratory 
interfaces. EDC includes the use of Electronic Case Report Forms 
(eCRFs) which are used to capture data transcribed from paper so urce 
forms used at the point of care.
End of the clinical trial The end of the clinical trial is defined as the last visit of the last subject or 
at a later point in time as defined by the protocol. 
Enrollment Point/time of subject entry into the study at which informed consent must 
be obtained 
eSource (DDE) eSource Direct Data Entry (DDE) refers to the capture of clinical study 
data electronically, at the point of care. eSource Platform/Applications 
reduce the use of paper capture source data during clinical visits. 
eSource combines source documents and case report forms (CRFs) into 
1 application, allowing for the real time collection of clinical trial 
information to sponsors and other oversight authorities, as appropriate.
Healthy volunteer A person with no known significant health problems who volunteers to be 
a study participant 
Investigational 
drug/treatmentThe drug whose properties are being tested in the study
Medication number A unique identifier on the label of medication kits
Mis-randomized 
subjectsMis-randomized subjects are those who were not qualified for 
randomization and who did not take study treatment, but have been 
inadvertently randomized into the study .
Other treatment Treatment that may be needed/allowed during the conduct of the study 
(concomitant or rescue therapy)
Part A sub -division of a study used to evaluate specific objectives or contain 
different populations. For example, one study could contain a single dose 
part and a mul tiple dose part, or a part in subjects with established 
disease and in those with newly -diagnosed disease.
Patient An individual with the condition of interest for the study
Period The subdivisions of the trial design (e.g. Screening, Treatment, Follow -
up) which are described in the Protocol. Periods define the study phases 
and will be used in clinical trial database setup and eventually in analy sis.

Novartis Confidential Page 11
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Personal data Subject information collected by the Investigator that is transferred to 
Novartis f or the purpose of the clinical trial. This data includes subject 
identifier information, study information and biological samples.
Premature subject 
withdrawalPoint/time when the subject exits from the study prior to the planned 
completion of all study drug administration and/or assessments; at this 
time all study drug administration is discontinued and no further 
assessments are planned.
Randomization number A unique identifier assigned to each randomized subject
Screen Failure A subject who did not m eet one or more criteria that were required for 
participation in the study
Source Data/Document Source data refers to the initial record, document, or primary  location 
from where data comes. The data source can be a database, a dataset, a 
spreadsheet or e ven hard -coded data, such as paper or eSource.
Start of the clinical trial The start of the clinical trial is defined as the signature of the informed 
consent by the first subject.
Study treatment Any single drug or combination of drugs or intervention a dministered to 
the subject as part of the required study procedures
Study treatment 
discontinuationWhen the subject permanently stops taking any of the study drug(s) prior 
to the defined study treatment completion date (if any) for any reason; 
may or m ay not also be the point/time of study discontinuation 
Subject A trial participant (can be a healthy volunteer or a patient)
Subject number A unique number assigned to each subject upon signing the informed 
consent. This number is the definitive, unique identifier for the subject 
and should be used to identify the subject throughout the study for all 
data collected, sample labels, etc.
Treatment arm/group A treatment arm/group defines the dose and regimen or the combination, 
and may consist of 1 or more cohorts.
Variable A measured value or assessed response that is determined from specific 
assessments and used in data analysis to evaluate the drug being tested 
in the study
Withdrawal of study 
consent Withdrawal of consent from the study occurs only when a subject does 
not want to participate in the study any longer, and does not allow any 
further collection of personal data

Novartis Confidential Page 14
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Section 4.6added for Public Health Emergency mitigation procedures. Section 6.7, 
Section 
7, Section 8, Section 8.3, Section 8.4 , Section 8.4.1 , Section 8.4.3 and Section 
8.5.2 have been updated accordingl y. Section 5.2 -Deletion of exclusion criterion #11 
pertaining to male contraception. All other relevant sections of the protocol have been 
updated to reflect this change ( Section 4.5, Section 7, Section 8.4.3 and Section 10.1.4 ).
Changes to specific sections of the protocol are shown in the track chan ges version of the 
protocol using strike through red font for deletions and red underlined for insertions .
IRBs/IECs
A copy of this amended protocol will be sent to the Institutional Review Board
(IRBs)/Independent Ethics Committee (I ECs) and Health Author ities.
The changes described in this amended protocol require IRB/IEC and Health Authority
approval according to local regulations prior to implementation.
The changes herein affect the Informed Consent. Sites are required to update and submit for
approval a revised Informed Consent that takes into account the changes described in this
protocol amendment.

Novartis Confidential Page 15
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Local Protocol A mendment 1 (for Canada onl y, 30-Oct-2019)
The purpose of this amendment is to:
1) Add a threshold for the estimated glomerular filtration rate (eGFR) to exclusion criterion #22
2) Update actions after detection of a renal adverse event.
Changes to protocol and rationale
Section 5.2 Exclusion criteria : Following the recommendation of Health Canada f or 
the preceding core study (CLOU064A2201), an eGFR <45 ml/min threshold was added
to exclusion criterion # 22.
Section 8.4.1 Laboratory evaluation: eGFR added to Table 8-10 Laborator y 
assessments.
Section 10.2.2 Renal safety monitoring: Following the recommendation of Health 
Canada for the preceding core stud y (CLOU064A2201), the timelines after detection of
a renal adverse event have been changed.
Section 16.3 Appendix 3: Specific renal alert criteria and actions and event 
follow -up: Following the request of Health Canada for the preceding core study 
(CLOU064A2201), necessary  actions after the detection of a renal adverse event have 
been clarified and a rise of serum creatinine ≥50% compared to baseline now leads to a 
mandatory  interruption of the investigational treatment.

Novartis Confidential Page 16
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Protocol A mendment 1 (02-Oct -2019) 
The main purpose of this amendment is to address requests from health authorities and to align 
eligibility  criteria of this study  with amended eligibility  criteria of the preceding core study 
CLOU064A2201:
Deletion of inclusion criterion #4 (this change triggers several changes throughout the 
document, including changing the study  title, modification of inclusion criterion #3  
).
Lowering the minimum required resting heart rate to 50 bpm (from 60 bpm) to align with 
amended exclusion criterion #6b in CLOU064A2201. This also aligns the eligibility  
criterion for resting heart rate with normal resting heart rates of CSU patients and does not 
impact patient safet y as LOU064 does not have a negative chronotropic effect.
Clarification that investigato rs need to assess the benefit -risk ratio for each subject 
throughout the study . Both, lack of or inadequate treatment response and/or emergence of 
adverse events that outweigh the benefits, can lead to study  treatment discontinuation.
Adding urine pregnanc y testing every  4 w eeks with at home assessments between study  
visits for women of childbearing potential starting after the Week 20 visit of the treatment 
period.
Additionally , editorial errors were addressed and clarity  was improved.
As the study  populat ion is affected, the changes described in this amended protocol require 
IRB/IEC approval prior to implementation. Additionally , some changes affect the Informed 
Consent. Sites are required to update and submit for approval a revised Informed Consent that 
takes into account the changes described in this protocol amendment.
Changes to protocol and rationale
Changes are shown in the track changes version of the protocol using strike through red font 
for deletions and red underlined for insertions . 
Section 5.1: Following a request from health authorities, inclusion criterion #4 (i.e. 
rollover of patients from not
-yet specified studies with LOU064) was deleted. 
Additionally , inclusion criterion #3 needed to be updated to inclusion criterion #3a in 
order to clarify
, that all subjects must have completed the Week 12 or Week 16 visit of 
CLOU064A2201 prior to enrollment into this extension study . As no patients from other 
studies can rollover from other not-yet specified preceding studi es anym ore, the 
reference to other preceding studies needed to be deleted in several sections of the 
protocol:
oProtocol title
oSection 1.2 (Purpose)
oSection 2 (Objectives and Endpoints, including Table 2-1)
oSection 3 (Study  Design, including Figure 3-1 )
oSection 5 (Population)
oSection 12.8.1 (Primary  Endpoints, in Section 12.8, Sample size calculation)
Section 5.2,exclusion criterion #6 has been updated to exclusion criterion #6a: This 
exclusion criterion aims toexclude 
patients with a pre-existing cardiac risk from 

Novartis Confidential Page 19
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
to the treatment period or the observational period of CLOU064A2201E1 based 
on the UAS7 score (of the 7 days prior to the respective visit) as follows:
Subjects rolling over at W eek 12 of CLOU064A2201 with a UAS7 ≥16 will be 
allocated to the Tr eatment period (note: subjects with UAS7<16 at Week 
12 are not eligible to roll -over into CLOU064A2201E1 but need to enter 
the follow -up period of CLOU064A2201).
Subjects rolling over at W eek 16 of CLOU064A2201 with a UAS7 ≥16 will be 
allocated to the Treat ment period.
Subjects rolling over at W eek 16 of CLOU064A2201 with a UAS7<16 will be 
allocated to the Observational period.
Key Exclusion 
criteriaSubjects having a clearly defined predominant or sole trigger of their chronic 
urticaria (chronic inducible urticaria) including urticaria factitia (sy mptomatic 
dermographism), cold -, heat -, solar -, pressure -, delayed pressure -, aquagenic -, 
cholinergic -, or contact -urticaria
Other diseases with symptoms of urticaria or angioedema, including but not limited 
to urticaria vasculitis, urticaria pigmentosa, erythem a multiforme, mastocy tosis, 
hereditar y urticaria, or acquired/drug -induced urticaria
Any other skin disease associated with chronic itching that might influence in the 
investigators opinion the study  evaluat ions and results, e.g. atopic dermatitis, 
bullous pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
History or current diagnosis of ECG abnormalities indicating significant risk of 
safety for subjects participating in the study such as:
Concomitant clinically significant cardiac arrhythmias, e.g. sustained 
ventricular tachy cardia, and clinically significant second or third degree AV 
block without a pacemaker
History of familial long QT syndrome or known family  history of Torsades de 
Pointes
Resting heart rate (as measured by 12 lead ECG) < 50 bpm
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at day 1 of the 
treatment period or inability to determine the QTcF interval
Use of agents known to prolong the QT interval unless it can be permanently 
discontinued for the duration of study
Significant bleeding risk or coagulation disorders
Known or suspected histor y of an ongoing, chronic or recurrent infectious disease 
including but not limited to opportunistic infections (e.g. tuberculosis , atypical 
mycobacterioses, listeriosis or aspergillosis), HIV, Hepatitis B/C
Study 
treatmentLOU064 capsules 50 mg
Efficacy 
assessmentsUrticaria Patient Daily Diar y (UPDD), including Urticaria Activity Score (UAS)

Novartis Confidential Page 21
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
1 Introduction
1.1 Background
Chronic Spontaneous Urticaria (CSU) is defined as the spontaneous occurrence of itchy  wheals 
(hives), angioedema or both lasting for at least 6 weeks (Zuberbier et al 2018). The classic 
description of urticaria is a wheal and flare with a pale elevated lesion and surrounding erythema, 
ranging in size from a few millimeters to a few centimeters across, usuall y occurring in groups 
and often coalescing to form large confluent lesions. CSU can be debilitating and is associated 
with intense itching and has a major impact on patient’s well-being, suggested to be comparable 
to that of severe coronary  artery  disease (Greaves 2003 ). The symptoms of urticaria and 
urticarial -associated angioede ma adversel y affect daily  activities and sleep (O'Donnell et 
al1997). The burden of CSU on health -related quality  of life (HRQoL) and work productivity 
is substantial ( Maurer et al 2017
).
Second generation H1- antihistamines are recommended as first line treatment for subjects with 
CSU but less than 40% of these subjects respond adequately  (Guillén- Aguinaga et al2016 ). 
While uptitra tion of second generation antihistamines is recommended b y most CSU treatment 
guidelines as second line therap y (Zuberbier etal2018), the efficacy of uptitrated H1-
antihistamines in CSU, beyond the approved label dose, has not been studied in larger clinical 
studies. Omalizumab is a highl y effective third line therap y for CSU subjects. However, less 
than 50% of subjects treated with omalizumab reach a complete control of signs and s ymptoms 
of CSU ( Kaplan et
al2016). Therefore, there is a high medical need for new treatment options 
for CSU subjects.
Bruton’s tyrosine kinase (BTK) is a cytoplasmic tyrosine kinase and member of the TEC kinase 
family . BTK is expressed in selec ted cells of the adaptive and innate immune system including 
B cells, 
macrophages, mast cells/basophils and thrombocy tes. BTK is indispensable for 
signaling through the Fc epsilon receptor (FcεR1 for IgE) and the activating Fc gamma 
receptors (FcγR for IgG), as well as the B cell antigen receptor (BCR) and BTK inhibitors 
(BTKi) like ibrutinib are approved for the treatment of B cell malignancies 
(Hendriks et al 2014 ). Recentl y, it has been demonstrated that inhibiti on of BTK leads to 
inhibition of mast cell and basophil activation/degranulation in vitro and to reduced wheal sizes 
in skin prick tests with patients suffering from IgE-mediated allergies (Smiljkovic et al 2017; 
Regan et
al2017; Dispenza et al2018 ). Thus, BTK inhibition is a promising therapeutic 
concept for the treatment of chronic urticaria.
LOU064 is a low molecular weight compound for oral administration that covalently binds and 
inhibits BTK with high selectivity . It has been shown to effectively  inhibit basophil activation 
in health y volunteers and CSU patients as measured by the inhibition of CD63 up-regulation. 
Addition ally, LOU064 reduced wheal sizes in skin prick tests. The 
pre-clinical and clinical 
safet y profile of LOU064 is favorable (for detailed information please refer to the Investigator`s 
Brochure (IB)). Thus, LOU064 may  offer a novel therapeutic option for tre ating CSU.
1.2 Purpose
The purpose of this study  is to evaluate long-term safet y and tolerability as well as efficacy 
outcome of LOU064 in patients who roll-over from CLOU064A2201.  

Novartis Confidential Page 23
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
3 Study  design
This study  is an open -label, single arm, multicenter, long -term safet y and tolerability extension 
study  for CSU patients rolling -over from CLOU064A2201. It consists of three periods ( Figure 
3-1):
Observational period: Subjects rolling over from CL OU064A2201 with UAS7<16 after 
the follow
-up period at Week 16 will be further followed up without receiving LOU064 
for up to 12 weeks. After relapse (UAS7≥16 at least once), the observational period can be 
terminated immediatel y at any time during these 12 weeks and subjects may  enter the 
treatment period. Continuation of background therap y with an H1 -antihistamine is at the 
discretion of the investigator; however, background therapy  should only  be interrupted in 
subjects with controlled CSU (e.g. UAS7 ≤6). Subjects who have never relapsed within 12 
weeks will discontinue the study  after the observational period.
Treatment period: Subjects will be treated with 100 mg LOU064 bid for 52 weeks. Until 
Week 4 of treatment, no background medication with H1 -antihist amines is permitted. 
After Week 4, subjects may  start a background therapy  with H1- antihistamines if deemed 
necessary  by the investigator.
Follow -up period: Treatment -free follow -up period following the treatment period. The 
minimum duration of treatment -free follow -up is 4 weeks for all subjects who stop 
treatment with LOU064 (either after completing the treatment period or after an earl y 
discontinuation of study  treatment). Subjects who have a UAS7 ≤6 at Week 52 of the 
treatment period will extend their f ollow -up period until relapse (UAS7 ≥16) for up to a 
total of 16 weeks.
Rescue therapy  to treat unbearable symptoms of urticaria on a day-to-day basis with an 
H1-antihistamine will be allowed throughout the study . A post-trial access program (which may 
be a
nother extension study or a managed access program) for subjects who complete this study 
is under consideration.

Novartis Confidential Page 24
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Figure 3-1 Study  design
1)Only when UAS7<16 at W eek 16 of CLOU064A2201: Treatment -free observational period for up to 
12 weeks. After relapse (UAS7≥16 at least once), subjects may immediately initiate treatment period. 
Subjects who have never relapsed within 12 weeks will discontinue the study after the obs ervational 
period. 
2)The minimum duration of the follow -up period will be 4 weeks for all subjects who stop treatment 
with LOU064. Subjects who achieve a UAS7≤6 at W eek 52 of the treatment period will extend their 
follow -up period until they relapse (UAS 7≥16). Follow -up will stop at W eek 68 for all subjects.
3)Background therapy is a second generation H1 -antihistamine at a locally approved licensed 
posology given with a stable treatment regimen. Administration/discontinuation of the background H1 -
antihis tamine is at the discretion of the investigator. Background therapy must not be taken from Day  1 
until W eek 4 of the Treatment period. It may be re -initiated at W eek 4 if deemed necessary.
4)Rescue therapy is a second generation H1 -antihistamine at a loca lly approved licensed posology 
that is eliminated primarily via renal excretion (e.g. cetirizine, levocetirizine or bilastine). The rescue 
H1-antihistamine must differ from the background H1 -antihistamine and may only be given to treat 
unbearable s ymptoms (itch) of CSU on a day -to-day basis.
Subjects rolling over from CLOU064A2201 will be assigned to one of the periods as follows 
(Figure 3-2):
Subjects with a UAS7 ≥16 at Week 12 or Week 16 will directly  enter the treatment period.
Subjects with a UAS7 < 16 at Week 12 will not rollover into the extension study  but enter 
the follow
-up period of the core stud y CLOU064A2201.
Subjects with a UAS7<16 at Week 16 (i.e., who have not relapsed during the follow -up 
period of CLOU064A22 01) will be assigned to the observational period.

Novartis Confidential Page 27
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
BTK inhibition may offer a new therapeutic principle for treating CSU that differs significantly 
from H1-antihistamines and anti-IgE biologics. BTK inhibition with LOU064 may therefore 
offer treatment options for patients with contraindications against or having an inadequate 
response to approved treatment options for CSU including biologics.
To date, 213 healthy  volunteers have received LOU064 up to 600 mg q.d. for up to 18 day s in 
four studies. In the study  CLOU064X2101, 30 healthy  volunteers received total daily doses 
≥100 mg for a period of 12 days. No serious or severe AE have been associated with the 
administration of LOU064, the majorit y of observed AEs were singular events and there was 
no relationship between LOU064 doses and AEs or the number of all observed AEs. A summary 
of AEs and of the pre -clinical safet y data can be found in the I nvestig ator’s Brochure (Sections 
4.3 and 5.2).
Based on a thorough review of safet y information currentl y available in the literature together 
with an assessment of safety  data obtained from both clinical and preclinical experience with 
LOU064, the following safe ty topics are considered as potential risks for LOU064 and require 
close monitoring in the proposed study . Of important note, many safety risks identified for 
ibrutinib and acalabrutinib, two BTK inhibitors approved for the treatment of B cell 
malignancies, are less likely related to the pharmacology of inhibition of the BTK, but rather to 
the underl ying indications being treated, for example, tumor lysis syndrome, second primar y 
malignancies, etc. Therefore, when comparing the safet y risks between the approved BTKi 
(e.g.: ibrutinib and acalabrutinib) and LOU064, the relevance and importance of the study 
patient populations must be taken into consideration.
Infections: BTK is an important signaling kinase downstream of cell surface receptors and 
expressed i n several immune cells of the adaptive and innate s ystem, including B cells, 
macrophages and mast cells/basophils. Therefore, LOU064 has the potential to increase 
the risk of infections. Patients with X -linked agammaglobulinemia (XLA) –a genetic 
defect as sociated with a lack of BTK – suffer from recurrent bacterial and enteroviral 
infections which may  be associated with neutropenia ( Kumar etal 2006). However, in 
XLA BTK -deficiency  leads to impaired B cell and plas ma cell development and in turn to 
a close to complete absence of immunoglobulins. Since BTK is not expressed in mature 
plasma cells, it is not expected that BTK inhibition in adults would lead to rapid or marked 
decrease in total immunoglobulin levels wit hin the study  time -frame. ( Hendriks et al 2014; 
Sunet
al2015; Nutt et al 2015 ). Administration of ibrutinib and acalabrutinib is associated 
with a risk of infection in patients suffering from B cell malignancies (see Summary  of 
Product Characteristics (SmPC) for ibrutinib and acalabrutinib). All patients participating 
in LOU064 clinical studies will be monitored closely  for signs a nd symptoms of infections 
while in the study. Patients with a known history  of chronic recurrent or active ongoing 
infections will be excluded from the stud y (refer to Section 5.2 for details).
Impaired platelet function: BTK is a signaling kinase in one of several platelet activation 
pathway s. In the prescribing information for both ibrutinib and acalabrutinib, 
bleeding/bruising events are very  common and affecting approximately  50% of patients 
with hematologic malignancies. Warnings on hemorrhagic events including deaths have 
also been described (see SmPC for ibrutinib and acalabrutinib). Compared to other drugs 
in the same class, LOU064 demonstrated a higher selectivity  for BTK vs. other TEC 
kinases. Thus, bleeding may  be le ss a safety concern when compared to ibrutinib and 
acalabrutinib. Patients receiving LOU064 must be closely  monitored for any  signs and 

Novartis Confidential Page 29
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
acalabrutinib, embry ofetal toxicity  in animals is reported (see SmPCs). Highl y effective 
methods of contraception must be practiced for women of child -bearing potential while 
taking stud y treatment and for 7 days after stopping stud y medicat ion.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study , and agree that in order 
to participate in the study they must adhere to the contraception requirements outlined in the 
exclusion criteria. I f there is any  question that the subject will not reliably  comply , they  should 
not enter or continue in the study .
In summary , CSU patients with inadequate response to H1-antihistamines and other avail able 
treatment options participating in this clinical trial may benefit from treatment with LOU064 
due to its impact on mast cell and basophil activation. Additionally , this study  will help improve 
the scientific understanding of LOU064 in the management of CSU and offer the potential of 
developing an innovative drug that could potentially  improve the qualit y of life for CSU patients 
beyond the conventional treatment modalities currently  available to them. Potential risks are 
mitigated by compliance with inclusion/exclusion criteria, study  procedures, close clinical 
monitoring and study  drug discontinuation rules. As with investigational drugs in general, not 
all safet y risks are known. Patients and investigators participating in this study  will be informed 
should important new safety  information become available.
4.6 Rationale for Public Health Emergency  mitigation procedures
During a Public Health emergency as declared b y Local or Regional authorities, i.e., pandemic, 
epidemic or natural disaster, mitigation procedures to ensure participant safety  and trial integrit y 
are listed in relevant sections. Notification of the Public health emergency  should be discussed 
with Novartis prior to implementation of mitigation procedures and permitted/approved by 
Local or Reg ional Health Authorities and Ethics Committees as appropriate .
5 Population
The study  population will consist of male and female adult CSU patients who received various 
doses of LOU064 or placebo in the core study  (CLOU064A2201). Subjects with a UAS7 ≥ 16 
atWeek 12 or Week 16 of the core study  will directly  enter the treatment period whereas 
subjects with a UAS7 < 16 at Week 16 of the core study  will be allocated to the observational 
period (see Section 3). In theory, all expecte d308 patients from the core trial CLOU064A2201 
could enter the extension protocol. However, we estimate that a
pproximately  250 patients will 
enroll into this extension study . 
5.1 Inclusion criteria
Subjects eligible for inclusion in this study  must meet allof the following criteria:
1.Written informed consent must be obtained before any  assessment is performed.
2.Willing and able to complete a dail y symptom eDiary  for the duration of the study  and 
adhere to the stud y visit schedules.
3a Subjects must have completed the Week 12 visit (end of treatment period) or the Week 16 
visit (end of the follow -up period) of CLOU064A2201 and will be allocated to the 

Novartis Confidential Page 30
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
treatment period or the observational period of CLOU064A2201E1 based on the UAS7 
score (of the 7 day s prior to the respective visit) as follows:
Subjects rolling over at Week 12 of CLOU064A2201 with a UAS7 ≥16 will be 
allocated to the Treatment period (note: subjects with UAS7<16 at Week 12 are not 
eligible to rollover into CLOU064A2201E1 but need to enter the follow- up period of 
CLOU064A2201).
Subjects rolling over at Week 16 of CLOU064A2201 with a UAS7 ≥16 will be 
allocated to the Treatment period.
Subjects rolling over at Week 16 of CLOU064A2201 with a UAS7<16 will be 
allocated to the Observ ational period.
5.2 Exclusion criteria
1. Use of other investigational drugs within 5 half- lives of enrollment, or within 30 day s (for 
small molecules) prior to enrollment or until the expected pharmacod ynamic (PD) effect 
has returned to baseline (for biologics), whichever is longer; or longer if required by  local 
regulations.
2.History  of hypersensitivity  to any  of the study  drugs or its excipients or to drugs of similar 
chemical classes.
3.Subjects having a clearly defined, predominant or sole trigger of their chron ic urticaria 
(chronic inducible urticaria) including urticaria factitia (symptomatic dermographism), 
cold- , heat -, solar -, pressure -, delay ed pressure -, aquagenic- , cholinergic -, or contact 
urticaria
4.Other diseases with sy mptoms of urticaria or angioedema, including but not limited to 
urticaria vasculitis, urticaria pigmentosa, ery thema multiforme, mastocy tosis, hereditary  
urticaria, or acquired/drug -induced urticaria
5.Any other skin disease associated with chronic itching that might influence in the 
investi gators opinion the study  evaluations and results, e.g. atopic dermatitis, bullous 
pemphigoid, dermatitis herpetiformis, senile pruritus or psoriasis
6a History  or current diagnosis of ECG abnormalities indicating significant risk of safet y for 
subjects pa rticipating in the study  such as:
Concomitant clinically  significant cardiac arrh ythmias, e.g. sustained ventricular 
tachycardia, and clinically significant second or third degree AV block without a 
pacemaker
History  of familial long QT sy ndrome or known f amily history  of Torsades de Pointes
Resting heart rate (as measured b y 12 lead ECG) < 50 bpm at day  1 of treatment
Resting QTcF ≥450 msec (male) or ≥460 msec (female) at day  1 of the treatment 
period or inability  to determine the QTcF interval
Use of agents known to prolong the QT interval unless they  can be permanently  
discontinued for the duration of study
7. Patients/subjects taking medications prohibited by the protocol 
(seeSection 6.2.2, Table 6-2)

Novartis Confidential Page 31
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
8.History  of malignancy  of any  organ s ystem (other than localized basal cell carcinoma of 
the skin or in situ cervical cancer), treated or untreated, within the past 5 y ears, regardless 
of whether there is evidence of local recurrence or metastase s.
9.Pregnant or nursing (lactating) women
10.Women of child- bearing potential, defined as all women physiologically  capable of 
becoming pregnant, unless they are using highl y effective methods of contraception during 
dosing and for 7 days after stopping study  medication. Highly  effective contraception 
methods include:
Total abstinence (when this is in line with the preferred and usual lifesty le of the 
subject). Periodic abstinence (e.g., calendar, ovulation, sy mptothermal, post -ovulation 
methods) and withdrawal are not acceptable methods of contraception
Female sterilization (have had surgical bilateral oophorectom y with or without 
hysterectom y) total hysterectom y or tubal ligation at least six weeks before taking 
investigational drug. In case of oophorectom y alo ne, only when the reproductive status 
of the woman has been confirmed b y follow up hormone level assessment
Male sterilization (at least 6 months prior to screening). For female subjects on the 
study , the vasectomized male partner should be the sole partner for that subject
Use of oral, (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or placement of an intrauterin e device (IUD) or intrauterine system (IUS) 
or other forms of hormonal contraception that have comparable efficacy  (failure rate 
<1%), for example hormone vaginal ring or transdermal hormone contraception
In case of use of oral contraception women should h ave been stable on the same pill for a 
minimum of 3 months before taking investigational drug.
Women are considered post -menopausal and not of child bearing potential if they  have 
had 12 months of natural (spontaneous) amenorrhea with an appropriate clinic al profile 
(e.g. age appropriate, history  of vasomotor s ymptoms) or have had surgical bilateral 
oophorectom y (with or without hy sterectomy ), total hy sterectom y or tubal ligation at least 
six weeks ago. In the case of oophorectomy  alone, only  when the repro ductive status of 
the woman has been confirmed by
 follow up hormone level assessment is she considered 
not of child bearing potential.
11.Exclusion criterion had become irrelevant.
12.Major surgery  within 8 weeks prior to enrollment or surgery  planned prior to e nd of the 
treatment period.
13.History  of live attenuated vaccine within 6 weeks prior to enrollment or requirement to 
receive these vaccinations at any  time during study  drug treatment
14.Evidence of clinically  significant cardiac, neurologic, ps ychiatric, pulm onary , renal, 
hepatic, endocrine, metabolic, hematological disorders or gastrointestinal disease that, in 
the investigator's opinion, would compromise the safet y of the participant, interfere with 
the interpretation of the study  results or otherwise preclu de participant participation.
15.Uncontrolled disease states, such as asthma, or inflammatory  bowel disease, where flares 
are commonl y treated with oral or parenteral corticosteroids
16.Hematology  parameters at last visit before Day  1 of the Treatment period (ei ther last 
available value from CLOU064A2201 or most recent value taken during observational 
period):

Novartis Confidential Page 32
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Hemoglobin: < 10 g/dl
Platelets: < 100 000/mm3
White blood cells: < 3 000/mm3
Neutrophils: < 1 500/mm3
17.Significant bleeding risk or coagulation disorders
18.History  of gastrointestinal bleeding, e.g. in association with use of Nonsteroidal Anti -
Inflammatory  Drug (NSAID)
19.Requirement for anti-platelet or anticoagulant medication (for example, warfarin, or 
clopidogrel or Novel Oral Anti- Coagulant - NOAC) other th an acet ylsalicy lic acid (up to 
100 mg/d)
20.History  or presence of thrombotic or thromboembolic event, or increased risk for 
thrombotic or thromboembolic event
21.History  or current treatment for hepatic disease including but not limited to acute or 
chronic hepa titis, cirrhosis or hepatic failure or Aspartate Aminotransferase 
(AST)/Alanine Aminotransferase (ALT) levels of more than 1.5 x upper limit of normal 
(ULN) at last visit before Day  1 of the Treatment period (either last available value from 
CLOU064A2201 o r most recent value taken during observational period)
22.History  of renal disease or creatinine level above 1.5x ULN at last visit before Day  1 of 
the Treatment period (either last available value from CL OU064A2201 or most recent 
value taken during observational period)
[Canada only : History  of renal disease, creatinine level above 1.5x ULN or eGFR 
<45ml/min (using the Cockcroft- Gault equation) at last visit before Day  1 of the 
Treatment period (either last available value from CL OU064A2201 or most recent val ue 
taken during observational period)]
23.Known or suspected history  of an ongoing, chronic or recurrent infectious disease 
including but not limited to opportunistic infections (e.g. tuberculosis, at ypical 
mycobacterioses, listeriosis or aspergillosis), HIV, Hepatitis B/C
No additional exclusions may be applied by the investigator, in order to ensure that the study  
population will be representative of all eligible subjects
6 Treatment
6.1 Stud y treatment
Novartis Global Clinical Supply  (GCS) will provide theIMP for the study . Background and 
concomitant medication will not be supplied by  Novartis GCS.
6.1.1 Investigational and control drugs
Table 6-1 Investigational drug
Investigational
DrugPharmaceutical 
Dosage FormRoute of 
AdministrationSupply type Sponsor (global 
or local)
LOU064 50 mg Hard gelatin 
capsuleOral use Open -label 
supplies, bottlesNovartis Pharma 
AG (Global)

Novartis Confidential Page 36
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
12hours. The subject must also be instructed to contact the investigator if he/she is unable for 
any reason to take the study  treatment as prescribed. Compliance with study  treatment will be 
recorded by the subject in the eDiary. In addition, compliance will be assessed by the 
investigator and/or study personnel at each visit using capsules counts and information provided 
by the subject and captured in the source document at each visit. All stud y treatment dispensed 
and returned must be recorded in the Drug Accountability  Log.
6.6.2 Emergency  breaking of a ssigned treatment code
Not applicable.
6.7 Preparation and dispensation
Each study  site will be supplied with study  drug in packaging as described under investigational 
and control drugs Section 6.1.1 .
An IRTsystem would be used in the study  for medication management purposes.
Investigator staff will identify  the study  medication kits to dispense to the subject by contacting 
the IRT and obtaining the medication number(s). The study medication has a 2 -part label (base 
plus tear-off label), immediately  before dispensing the medication kit to the subject, site 
personnel will detach the outer part of the label from the packaging and affix it to the source 
document.
At each dispensation visit, study  personnel delegated for this activity  would contact IRTand 
provide the patient with the assigned bottles to accommodate patient needs till the next 
dispensation visit. The number of bottles dispensed would vary depending on the duration 
between visits.
As per Section 4.6, during a Public Health emergency  as declared by Local or Regional 
authorities, i.e., pandemic, epidemic or natural disaster, that limits or prevents on-site study 
visits, delivery  of IMP directl y to a participant’s home may be permitted (if allowed by Local 
or Regional Health Authorities and Ethics Committees as appropriate) in the event the 
Investigator has decided that an on-site visit by the participant is no longer appropriate or 
possible and that it is in the i nterest of the participant’s health to administer the study  treatment 
even without performing an on -site visit. The dispatch of IMP from the site to the participant’s 
home remains under the accountability of the I nvestigator. Each shipment/provisioning wil l be 
for a maximum of one -month supply . In this case, regular phone calls or virtual contacts (ever y 
4 weeks or more frequently  if needed) will occur between the site and the 
participant for 
instructional purposes, safet y monitoring, drug accountability , investigation of any adverse 
events, ensuring participants continue to benefit from treatment, and discussion of the 
participant’s health status until the participants can resume visits at the study site.
6.7.1 Handling of study treatment and additional treatment
6.7.1.1 Handling of study  treatment
Study  treatment must be received by a designated person at the study  site, handled and stored 
safel y and properl y and kept in a secured location to which only the investigator and designated 
site personnel have access. Upon receipt, all study  treatment must be stored according to the 

Novartis Confidential Page 38
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
If applicable, in cases where the subject's represe ntative(s) gives consent (if allowed according 
to local requirements), the subject must be informed about the study  to the extent possible given 
his/her understanding. If the subject is capable of doing so, he/she must indicate agreement by 
personall y sign ing and dating the written informed consent document.
Informed consent must be obtained before conducting any study-specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the subject source documents.
Novartis will provide to investigators in a separate document a proposed informed consent form 
that complies with the ICH GCP guidelines and regulatory  requirements and is considered 
appropriate for this study . Any changes to the proposed consent form suggested by the 
investigator must be agreed by  Novartis before submission to the I RB/IEC.
Information about common side effects alread y known about the investigational drug can be 
found in the Investigator's Brochure (IB). This information will be included in the subject 
informed consent and should be discussed with the subject during the study  as needed. Any new 
information regarding the safet y profile of the investigational drug that is identified between IB 
updates will be comm unicated as appropriate, for example, via an investigator notification or 
an aggregate safet y finding. New information might require an update to the informed consent 
and then must be discussed with the subject.
Women of child bearing potential must be informed that taking the study  treatment may involve 
unknown risks to the fetus if pregnancy  were to occur during the study  and agree that in order 
to participate in the study they  must adhere to the contraception requirements.
A copy of the approved version of all consent forms must be provided to Novartis/sponsor after 
IRB/IEC approval.
The study  includes the option for the participant to have certain study  procedures performed 
off-site by an off-site healthcare professional instead of at the study  site, forwhich a separate 
signature is required if the participant agrees. It is required as part of this protocol that the 
Investigator presents this option to the participant, as permitted by  national and local governing 
regulations. The process for obtaining consent should be exactly  the same as described above 
for the main informed consent.
As per Section 4.6, during a Public Health emergency  as declared by Local or Regional 
authorities i.e. pandemic, epidemic or natural disaster, that may challenge the ability  to obtain 
a standard written informed consent due to limits that prevent an on -site visit, I nvestigator may 
conduct the informed consent discussion remotely  (e.g. telephone, videoconference) if 
allowable b y a local Health Au
thority .
Guidance issued by local regulatory  bodies on this aspect prevail and must be implemented and
appropriatel y documented (e.g. the presence of an impartial witness, sign/dating separate ICFs
by trial participant and person obtaining informed consent , etc.).
8 Visit schedule and assessments
The assessment schedule lists all of the assessments and indicates with an “X” or “S”, the visits 
when they are performed. All data obtained from these assessments must be supported in the 
subject’s source documentat ion.

Novartis Confidential Page 39
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Subjects should be seen/contacted for all visits/assessments as outlined in the assessment 
schedule or as close to the designated day/time as possible. Missed or rescheduled visits should 
not lead to automatic discontinuation.
As per Section 4.6, during a Public Health emergency  as declared by Local or Regional 
authorities, i.e., pandemic, epidemic or natural disaster that limits or prevents on-site study  visits, 
alternative methods of providing continuing care may be implemented by the investigator as 
the situation dictates. If allowed by local Health Authority  and depending on operational 
capabilities, phone calls, virtual contacts (e.g., tele co nsult) or visits by  site staff/ home nursing 
staff to the participant’s home 
can replace on -site study  visits for the duration of the disruption 
until it is safe for the participant to visit the site again.

Novartis Confidential Page 44
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
X: recorded in the eCRF; S: recorded in the source documents only 
1UPDD: Urticaria Patient Daily Diary; UAS: Urticaria Activity Score; 
3Only assess if day 1 of observational period is more than 1 week after W eek 16 of core study
4If CSU relapse is detected at the visit: please directly perform an EoOP visit instead of the preplanned day 29 or day 57 vis it
5EoOP: End of Observational Period can be directly after a CSU relapse (defined as UAS7 ≥16) was detected (either during a sc heduled or an unscheduled visit); in case, 
EoOP and day 1 of the treatment period are at the same day, assessments only need to be done once.

Novartis Confidential Page 45
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
8.1 Screening
At day 1 of the treatment period and at day 1 of the observational period (if applicable), all 
inclusion and exclusion criteria will be checked. For all laboratory  assessments, the results from 
the last visit before Day 1 of the treatment period (either the last available value from 
CLOU064A2201 or most recent value taken during observational period) will be used. 
Eligibility  for this study  will be assessed at Week 12 and Week 16 of the preceding core study 
CLOU064A2201. Subjects who are not eligible for enrollment into this extension study  at 
Week 12 for any reason will not be assigned to a subject number for this extension study  but 
will enter the follow -up period of CLOU064A2201. Re-screening of subjects who are not 
eligible at Week 16 is not permitted. 
8.1.1 Information to be collected on screening failures
Patients who sign an informed consent but fail to be started on treatment for any reason other 
than never relapsing during the observational period will be considered a screen failure. The 
reason for not being started on treatment will be entered on the screening phase disposition page. 
The demographic information, informed consent, and Inclusion/Exclusion pages must also be 
completed for screen failure patients. No other data will be entered into the clini cal database for 
patients who are screen failures, unless the patient experienced a serious adverse event during 
the screening phase (see SAE Section for reporting details). 
8.2 Subject demographics/other baseline characteristics
Baseline CSU activit y will beassessed using the eDiary  from Day -7 to Day -1 of the day 1 
visit of the treatment period. Subject demographic and baseline characteristic data including 
sex, race and ethnicity  that was collected as a part of the core study  will be used for this 
extensi on study . Relevant medical history  (including evaluation of inclusion/exclusion criteria, 
CSU history  and cardiovascular history ) and current medical condition present before signing 
the informed consent will be captured. Where possible, diagnoses, and notsymptoms, will be 
recorded. Data on subjects’ family  history  of malignancies will be collected on the respective 
eCRF page, only when a subject has a malignancy event reported during the study , to assess 
possible risk factors related to any  malignancies.
Country  specific regulations should be considered for the collection of demographic and 
baseline characteristics in alignment with eCRF.
8.3 Efficacy
All subjects will be provided with an electronic device (eDiary ) that contains the following 
assessments: Urticaria Patient Daily Diary  (UPDD),  
.
Site and subjects will receive appropriate training and guidance on the use of the eDiary  and 
will receive clear instructions on the completion ofthe assessments. Investigators need to 
review the eDiary  at every  visit.
Assessments will be completed twice daily  (UPDD),  
 or as detailed in the assessment schedule. 

Novartis Confidential Page 47
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Table 8-4 Hives Severity  Score
Score Hives (Wheals) (every 12 hours)
0 None
1 1-6 hives/12 hours
2 7-12/12 hours
3 > 12 hives/12 hours
8.3.1.1.2 Weekly Itch Severity Score (ISS7)
The severit y of the itch will be recorded by the subject twice daily in their eDiary, on a scale of 
0 (none) to 3 (severe) (Table 8-5). A weekly  score (ISS7) is derived by adding up the average 
daily  scores of the 7 days preceding the visit. The possible range of the weekly  score is therefore 
0 - 21.
Table 8
-5 Itch Severity  Score
Score Pruritus (Itch) (every 12 hours)
0 None
1 Mild (minimal awareness, easily tolerated)
2 Moderate (definite awareness, bothersome but tolerable)
3 Severe (difficult to tolerate)
8.3.1.1.3 Weekly Urticaria Activity Score (UAS7)
The UAS7 is the sum of the HSS7 score and the ISS7 score. The possible range of the weekly 
UAS7 score is 0 –42 (highest activity ).

Novartis Confidential Page 48
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1

Novartis Confidential Page 50
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Main safet y and tolerability  assessments include:
AEs and SAEs, including AEs leading to treatment discontinuation and events of interest 
such as infections, bleeding/bruising, QT -prolongation and my elomodulating effects (i.e. 
cytopenias)
Physical examination
Vital signs
Laboratory  evaluations
ECG
Table 8-9 Physical A ssessments
Assessment Specification
Physical 
examinationA complete physical examination (performed at enrollment, see Table 8-1) will 
include the examination of general appearance, skin, neck (inc luding thyroid), 
eyes, ears, nose, throat, lungs, heart, abdomen, back, ly mph nodes, extremities, 
vascular, and neurological. If indicated based on medical history and/or 
symptoms, rectal, external genitalia, breast, and pelvic exams will be performed.
A short phy sical exam (performed at visits indicated 
in Table 8-1and Table 8-2) will include the examination of general 
appearance, assessment of the skin for sign of urticaria and other skin lesio ns, 
and vital signs (blood pressure [SBP and DBP] and pulse).
Information for all physical examinations must be included in the source 
documentation at the study site. Clinically relevant findings that are present prior 
to signing informed consent must be recorded on the appropriate eCRF that 
captures medical histor y. Significant findings made after signing the informed 
consent which meet the definition of an AE must be recorded as an AE.
Vital signs Vital signs include BP and pulse measurements. After the subject has been 
sitting for five minutes, with back supported and both feet placed on the floor, 
systolic and diastolic blood pressure will be measured three times using an 
automated validated device, e.g. OMRON, with an appropriately sized cuff. The 
repeat sitting measurements will be made at 1 -2 minute intervals and the mean 
of the three measurements will be used. In case the cuff sizes available are not 
large enough for the subject's arm circumference, a sphygmomanometer with an 
appropriately sized c uff may be used.
Clinically notable vital signs are defined in Section 16.1.
Height and 
weightHeight in centimeters (cm) and body weight (to the nearest 0.1 kilogram (kg) in 
indoor clothing, but without shoes) will be meas ured.
As per Section 4.6 , during a Public Health emergency  as declared by Local or Regional 
authorities, i.e., pandemic, epidemic or natural disaster, that limits or prevents on-site study 
visits, regular phone or virtual ca lls can occur (every 4 weeks or more frequently if needed) for 
safet y monitoring and discussion of the participant’s health status until it is safe for the 
participant to visit the site again.
8.4.1 Laboratory  evaluations
A central laboratory  will be used for analysis of all specimens detailed in this section 
(Table 8-10) unless noted otherwise. Details on the collections, shipment of samples and 
reporting of results by the central laboratory  are provided to investigators in the 
laboratory 
manual.

Novartis Confidential Page 51
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
If participants cannot visit the site for protocol specified safety  lab assessments (per Section 4.6), 
an alternative lab (local) collection may  be used.
Clinically  notable laboratory  findings are defined in Appendix 1 .
Clinically  significant abnormalities must be recorded on the relevant section of the eCRFs 
capturing medical history/current medical conditions/AEs.
Table 8-10 Laboratory  assessments
Test Category Test Name
Hematology Hematocrit , Hemoglobin [only in case of clinically significant anemia, the 
following parameters will be assessed: Mean Corpuscular Hemoglobin (MCH), 
Mean Corpuscular Hemoglobin Concentration (MCHC), Mean Corpuscular 
Volume (MCV)], Platelets, Red blood cells (RBC), White blood cells (W BC) and 
Differential (Basophils, Eosinophils, Ly mphocy tes, Monocytes, Neutrophils , 
Bands)
Chemistry Albumin, Alkaline phosphatase (ALP), ALT, AST , Gamma -glutam yl-
transferase (GGT), Lactate dehydrogenase (LDH), Calcium, Magnesium, 
Phosphorus, Chloride, Sodium, Potassium, Creatine Kinase (CK), Creatinine, 
total Bilirubin (in case of clinically significant elevation: direct Bilirubin and 
indirect Bilirubin will be assessed), [Canada only : eGFR]
Only at baseline (day 1), W eek 28 and 52: total Cholesterol, Low density 
Lipoprotein (LDL), High density Lipoprotein (HDL), Total Protein, Triglycerides, 
Blood Urea Nitrogen (BUN) or Urea, Uric Acid, Amylase, Lipase, Glucose 
(fasting)
Only at baseline and when deemed necessary by the investigator: C -reactive 
Protein (CRP)
Urinalysis Done on site: Macroscopic Panel (Dipstick) (Color, Bilirubin, Blood, Glucose, 
Ketones, Leukocytes esterase, Nitrite, pH, Protein, Specific Gravity, 
Urobilinogen)
Coagulation Prothrombin time (PT)/International normalized ratio (INR), Activated partial 
thromboplastin time (APTT)
Additional tests IgE, serum pregnancy test (for WoCBP)
Pregnancy Test Urine pregnancy test for WoCBP
8.4.2 Electrocardiogram (ECG)
ECGs will be analy zed centrall y and performed with ECG machines supplied by the central 
provider. Standard 12-lead ECGs (single readings) must be recorded after 10 minutes rest in the 
supine position accord ing to the ECG investigator manual at the timepoints indicated 
inTable 8-1. The preferred sequence of cardiovascular data collection during study  visits is 
ECG collection first, followed by vital signs, and blood sampling. The Fridericia QT correction 
formula (QTcF) should be used for clinical decisions.
For an y ECGs with treatment emergent abnormalities, two additional ECGs must be performed 
to confirm the abnormal finding and copies forwarded to the central ECG laboratory  for
assessment. A monitoring or review process should be in place for clinically  significant ECG 
findings throughout the study  and especially  at baseline before administration of study  
treatment.

Novartis Confidential Page 54
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
lack of or inadequate response to study  treatment in the opinion of the investigator 
and/or the subject,
emergence of AEs that outweigh the benefits of study  treatment in the opinion of the 
investigator and/or the subj ects.
Study  treatment must be discontinued under the following circumstances:
Subject decision
Pregnancy
Use of prohibited treatment as per recommendations in the prohibited treatment section
Any situation in which study  participation might result in a safet y risk to the subject, e.g. 
required surgical interventions associated with a risk for clinically  significant bleeding
Emergence of the following AEs:
AEs including h ypersensitivity  reactions, severe/serious infections (i.e., requiring 
specific intrav enous/intramuscular anti- infectious therap y and/or hospitalization), 
thromboembolism, clinically  significant spontaneous bleeding events and clinically  
significant ECG abnormalities (e.g. QT prolongation) for which continued exposure 
to the study  drug woul d be detrimental
Abnormal liver laboratory  results requiring discontinuation(see 
Appendix 2 )
Abnormal renal laboratory results requiring discontinuation (see Appendix 3 )
Platelets < 75 000/mm3
Any other laboratory  abnormalities that in the judgment of the investigator, taking 
into consideration the subject’s overall status, prevents the subject from continuing 
participation in the study
Patient received a live virus vaccination during the study
If discontinuation of study  treatment occurs, the investigator should make a reasonable effort 
to understand the primary reason for the subject’s premature discontinuation of study treatment 
and record this information.
Subjects who discontinue study  treatment or who decide they do not wish to participate in the 
study  further should NOT be considered withdrawn from the study  UNLESS 
they withdraw 
their consent (see withdraw of informed consent, Section 9.1.2). Subjects shoul d perform the 
End
-of-Treatment visit (EoTV) as quickl y after their last dose as possible. Then, subjects should 
be asked to return to the study site 4 weeks later for Study Completion Visit (SCV). If they fail 
to return for these assessments for unknown re asons, every  effort (e.g. telephone, e -mail, letter) 
should be made to contact the subject/pre -designated contact as specified in the lost to follow -
up section. This contact should preferabl y be done according to the stud y visit schedule.
If the subject ca nnot or is unwilling to attend any  visit(s), the site staff should maintain regular 
telephone contact with the subject, or with a person pre-designated by the subject. This 
telephone contact should preferably be done according to the study visit schedule.
After study  treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:
new / concomitant treatments
adverse events/Serious Adverse Events

Novartis Confidential Page 55
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
The investigator must als o contact the IRT to register the subject’s discontinuation from study  
treatment.
9.1.2 Withdrawal of informed consent
Subjects may voluntarily  withdraw consent to participate in the study  for any reason at any time. 
Withdrawal of consent occurs onl y when a su bject:
Does not want to participate in the study  anymore
and
Does not want an y further visits or assessments
and
Does not want an y further study related contacts
and
Does not allow anal ysis of already  obtained biologic material
In this situation, the investigator should make a reasonable effort (e.g. telephone, e -mail, letter) 
to understand the primary reason for the subject’s decision to withdraw his/her consent and 
record this information.
Study  treatment must be discontinued and no further assessments conducted, and the data that 
would have been collected at subsequent visits will be considered missing.
Further attempts to contact the subject are not allowed unless safety  findings require 
communicating or follow -up.
All efforts should be made to complete the assessments prior to study  withdrawal. A final 
evaluation at the time of the subject’s study  withdrawal should be made as detailed in the 
assessment table.
Novartis will continue to retain and use all research results (data) that have alread y been
collected for the study  evaluation.
9.1.3 Lost to follow -up
For subjects whose status is unclear because they  fail to appear for study  visits without stating 
an intention to discontinue or withdraw, the investigator must show "due diligence" by 
documenting in the source documents steps taken to contact the subject, e.g. dates of telephone 
calls, registered letters, etc. A subject should not be considered as lost to follow -up until due 
diligence has been completed or until the end of the study .
9.1.4 Early  study termi nation by  the sponsor
The study  can be terminated by  Novartis at any time for any  reason. This may  include reasons 
related to the benefit/risk assessment of participating in the study , practical reasons (including 
slow enrollment), or for regulatory  or medical reasons. In taking the decision to terminate, 
Novartis will alway s consider the subject welfare and safet y. Should early  termination be 
necessary , subjects must be seen as soon as possible (provide instruction for contacting the 
subject, when the subject should stop taking drug, when the subject should come for a final 
visit) and treated as a prematurel y withdrawn subject. The investigator may be informed of 

Novartis Confidential Page 56
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
additional procedures to be followed in order to ensure that adequate consideration is given to 
the protection of the subject’s interests. The investigator or sponsor depending on the local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.
9.2 Stud y completion and post -study  treatment
Study  completion is def ined as when the last subject finishes their Study  Completion visit, and 
any repeat assessments associated with this visit have been documented and followed -up 
appropriatel y by the Investigator, or in the event of an early study termination decision, the date 
of that decision.
In the event of an earl y study  termination, all subjects should perform the Week 52 visit (End -
of
-Treatment visit) as quickly  as possible after their last dose and the Week 56 Follow -up visit 
(4 weeks later).
A post-trial access progr am (which may be another extension study  or a managed access 
program) for subjects who complete this study  is under consideration.
10 Safety  monitoring and reporting
10.1 Definition of adverse events and reporting requirements
10.1.1 Adverse events
An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and 
unintended sign [including abnormal laboratory  findings], sy mptom or disease) in a subject or 
clinical investigation subject after providing written informed consent for participation in the 
study . Therefore, an AE may  or may  not be temporally  or causall y associated with the use of a 
medicinal (investigational) product.
The investigator has the responsibility  for managing the safet y of individual subject and 
identify ing adverse events.
Novartis qualified medical personnel will be readily  available to advise on trial related medical 
questions or problems.
The occurrence of adverse events must be sought by non -directive questioning of the subject at 
each visit during the study. Adverse eve nts also may  be detected when they are volunteered b y 
the subject during or between visits or through physical examination findings, laboratory  test 
findings, or other assessments.
Adverse events must be recorded in the Adverse Events CRF under the signs, symptoms or 
diagnosis associated with them, accompanied by  the following information (as far as possible) 
(if the event is serious refer to Section 10.1.2):
1.The severit y grade
mild: usually  transient in nature and general ly not interfering with normal activities
moderate: sufficiently  discomforting to interfere with normal activities
severe: prevents normal activities

Novartis Confidential Page 57
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
2.its relationship to the study  treatment. If the event is due to lack of efficacy or progression 
of underl ying illness (i.e. progression of the study  indication) the assessment of causalit y 
will usually  be ‘Not suspected’. The rationale for this guidance is that the sy mptoms of a 
lack of efficacy  or progression of underly ing illness are not caused by  the trial drug, they  
happen in spite of its administration and/or both lack of efficacy  and progression of 
underly ing disease can only  be evaluated meaningfull y by an anal ysis of cohorts, not on a 
single subject
3.its duration (start and end dates) or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.
4.whether it constitutes a SAE (see Section 10.1.2 for definition of SAE) and which 
seriousness criteria have been met
5.action taken regarding with study  treatment.
All adverse events must be treated appropriately . Treatment may include one or more of the 
following:
Dose not changed
Dose Reduced/increased
Drug interrupted/withdrawn
6.its outcome 
not recovered/not resolved
recovered/resolved
recovering/resolving
recovered/resolved with sequelae
fatal
unknown
Conditions that were alread y present at the time of informed consent should be recorded in 
medical history  of the subject.
Adverse events (including lab abnormalities that constitute AEs) should be described using a 
diagnosis whenever possible, rather than individual underly ing signs and s ymptoms.
Adverse event monitoring should be continued for at least 30 daysfollowing the last dose of 
study  treatment.
Once an adverse event is detected, it must be followed until its resolution or until it is judged to 
be permanent (e.g. continuing at the end of the study ), and assessment must be made at each 
visit (or more frequently, if necessary) of an y changes in severity, the suspected relationship to 
the interventions r equired to treat it, and the outcome.
Information about adverse drug reactions for the investigational drug can be found in the IB.
Abnormal laboratory  values or test results constitute adverse events only if they fulfill at least 
one of the following crit eria:
they induce clinical signs or sy mptoms
they are considered clinically  significant
they require therapy

Novartis Confidential Page 58
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Clinically  significant abnormal laboratory  values or test results must be identified through a 
review of values outside of normal ranges/clinically notable ranges, significant changes from 
baseline or the previous visit, or values which are considered to be non -typical in subjects with 
the underl ying disease. See Appendix 1, Appendix 2a nd Appendix 3for alert ranges for 
laboratory  and other test abnormalities.
10.1.2 Serious adverse events
A SAE is defined as any AE [appearance of (or worsening of any pre-existing)] undesirable 
sign(s), s ymptom(s) or medical conditions(s)) which meets an y one of the following criteria:
fatal
life-threatening
Life-threatening in the context of a SAE refers to a reaction in which the subject was at risk of 
death at the time of the reaction; it does not refer to a reaction that hypothetically might have 
caused death if it were more severe (please refer to the I CH-E2D Guidelines).
results in persistent or significant disability /incapacity
constitutes a congenital anomaly /birth defect
requires inpatient hospitalization or prolongation of existing hospitalization, unless 
hospitalization is for: 
routine treatment or monitoring of the studied indication, not associated with any  
deterioration in condition
elective or pre -planned treatment for a pre -
existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent
social reasons and respite care in the absence of any  deterioration in the subject’s 
general condition
treatment on an eme rgency  outpatient basis for an event not fulfilling any  of the 
definitions of a SAE given above and not resulting in hospital admission
is medically  significant, e.g. defined as an event that jeopardizes the subject or may  
require medical or surgical intervention to prevent one of the outcomes listed above
Medical and scientific judgment should be exercised in deciding whether other situations should 
be considered serious reactions, such as important medical events that might not be immediately 
life threate ning or result in death or hospitalization but might jeopardize the subject or might 
require intervention to prevent one of the other outcomes listed above. Such events should be 
considered as “medicall y significant”. Examples of such events are intensive treatment in an 
emergency  room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do 
not result in hospitalization or development of dependency  or abuse.
All malignant neoplasms will be assessed as serious under “medically  signific ant” if other 
seriousness criteria are not met.
Any suspected transmission via a medicinal product of an infectious agent is also considered a 
serious adverse reaction.
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred (see details in Section 10.1.5).

Novartis Confidential Page 59
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
10.1.3 SAE reporting
To ensure subject safet y, every  SAE, regardless of causalit y, occurring after the subject has 
provided informed consent and until 30 daysfollowing the last administration of study 
treatment must be reported to Novartis safet y within 24 hours of learning of its occurrence. 
Detailed instructions regarding the submission process and requirements are to be found in the 
investigator folder provided to each site.
No pre -specified study  endpoints are considered to be exempted from SAE reporting.
1. Screen Failures (e.g. a subject who is screened but is not treated or randomized): SAEs 
occurring after the subject has provided informed consent until the time the subject is 
deemed a Screen Failure must be reported to Novartis within 24 -hours of learning of its 
occurrence.
2. Randomized OR Treated Subjects: SAEs collected between time subject signs ICF until 
30 day s after the subject has discontinued or stopped study  treatment.
All follow -up information for the SAE including information on complications, progression of 
the initial SAE and recurrent episodes must be reported as follow -up to the original episode 
within 24 hours of the inv estigator receiving the follow -up information. An SAE occurring at a 
different time interval or otherwise considered completely  unrelated to a previously  reported 
one must be reported separatel y as a new event.
If the SAE is not previously documented in th e Investigator’s Brochure or Package Insert (new 
occurrence) and is thought to be related to the study  treatment, a CMO & PS Department 
associate may urgentl y require further information from the investigator for health authorit y 
reporting. Novartis may need to issue an Investigator Notification (IN) to inform all 
investigators involved in any study  with the same study  treatment that this SAE has been 
reported.
Suspected Unexpected Serious Adverse Reactions (SUSARs) will be collected and reported to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/01 or as per national regulatory requirements in participating countries.
Any SAEs experienced after the 30 day period following the last administration of study  
treatment should only be reported to Novartis Safety  if the investigator suspects a causal 
relationship to study  treatment.
10.1.4 Pregnancy  reporting
To ensure subject safety, each pregnancy occurring after signing the informed consent must be 
reported to Novarti swithin 24 hours of learning of its occurrence. The pregnancy  should be 
followed up to determine outcome, including spontaneous or voluntary  termination, details of 
the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal 
and/or newborn complications.
Pregnancy  should be recorded and reported by the investigator to the Novartis Chief Medical 
Office and Patient Safety  (CMO&PS). Pregnancy  follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study  treatment. Any  
SAE experienced during pregnancy  must be reported.

Novartis Confidential Page 60
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
10.1.5 Reporting of study treatment errors including misuse/abuse
Medication errors are unintentional errors in the prescribing, dispensing, administration or 
monitoring of a medicine while under the control of a healthcare professional, subject or 
consumer (EMA definition).
Misuse refers to situations where the medicinal product is intentionally  and inappropriatel y used 
not in accordance with the protocol.
Abuse corresponds to the persistent or sporadic, intentional excessive use of a medicinal product, 
which is accompanied b y harmful ph ysical or ps ychological effects.
Study  treatment errors and uses outside of what is foreseen in the protocol will be collected in 
the DAR (dose administration record) eCRF irrespective of whether or not associated with an 
AE/SAE and reported to Safety  only if associated with a SAE. Misuse or abuse will be collected 
and reported in the safety  database irrespective of it being associated with an AE/SAE within 
24 hours of Investigator’s awareness.
Table 10
-1 Guidance for capturing the study  treatment errors including 
misuse/abuse
Treatment error type Document in A E eCRF Complete SA E form
Unintentional study treatment 
errorOnly if associated with an AE Only if associated with an SAE
Misuse/Abuse Yes Yes, even if not associated with 
a SAE
For more information on AE and SAE definition and reporting requirements, please see 
Section 10.1.1, Section 10.1.2, and Section 10.1.3.
10.2 Additional Safety Monitoring
10.2.1 Liver safety monitoring
To ensure subject safety  and enhance reliability  in determining the hepatotoxic potential of an 
investigational drug, a standardized process for identification, monitoring and evaluation of 
liver events has to be follow ed.
The following two categories of abnormalities / adverse events have to be considered during 
the course of the study  (irrespective of whether classified/reported as AE/SAE):
Liver laboratory  triggers, which will require repeated assessments of the abnor
mal 
laboratory  parameter
Liver events, which will require close observation, follow- up monitoring and completion 
of the standard base liver CRF pages
Please refer to Table 16-1 in Appendix 2forcomplete definitions of liver laboratory  triggers 
and liver events.
Every  liver event defined in Table 16-1 should be followed up by the investigator or designated 
personnel 
at the trial site, as summarized below. Additional details on actions required in case 
of liver events are outlined in Table 16-2
.

Novartis Confidential Page 61
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Repeat liver chemistry  tests (AL T, AST, TBL, PT/I NR, ALP and G -GT) to confirm 
elevation. These liver chemistry  repeats will be performed using th e central laboratory . If 
results will not be available from the central laboratory , then the repeats can also be 
performed at a local laboratory  to monitor the safety  of the subject. If a liver event is 
subsequently  reported, any  local liver chemistry  tests previously  conducted that are 
associated with this event should have results recorded on the appropriate eCRF.
If the initial elevation is confirmed, close observation of the subject will be initiated, 
including consideration of treatment interruption if deemed appropriate.
Discontinuation of the investigational drug (refer to the Discontinuation of study  treatment 
section), if appropriate
Hospitalization of the subject if appropriate
Causality  assessment of the liver event
Thorough follow -up of the liver event. These investigations can include based on 
investigator’s discretion: serology  tests, imaging and pathology  assessments, 
hepatologist’s consultancy
Obtaining a more detailed history  of symptoms and prior or concurrent diseases.
Obtaining a history  of concomitant drug use (including nonprescription medications and 
herbal and dietary  supplement preparations), alcohol use, recreational drug use, and 
special diets.
Exclusion of underly ing liver disease
Imaging such as abdominal US, CT or MRI , as appropriate
Obtaining a history  of exposure to environmental chemical agents.
Considering gastroenterology  or hepatology  consultations.
All follow -
up information, and the procedures performed must be recorded as appropriate in 
the eCRF.
10.2.2 Renal safety  monito ring
The following two categories of abnormal renal laboratory values have to be considered during 
the course of the study : 
Serum creatinine increase ≥ 25% compared to baseline during normal h ydration status
Urine protein
-creatinine ratio ≥1g/g or ≥100 mg/mmol, OR new onset dipstick proteinuria ≥ 
3+ OR new onset dipstick hematuria ≥ 3+ (after excluding menstruation, Urinary 
Tract Infection (UTI), extreme exercise, or trauma)
Renal event findings must be confirmed after ≥24 hours but ≤ 5 day s after first a ssessment. 
[Canada only : Renal event findings must be confirmed within ≤ 5 days after first assessment].
Every  renal laboratory  trigger or renal event as defined in Table 16 -3in Appendix 3 should be 
followed up b y the investigator or designated personnel at the trial site as summarized in Table 
16-4 in Appendix 3 . 

Novartis Confidential Page 62
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
10.2.3 Data Monitoring Committee
In contrast to the core study  CLOU064A2201, this extension study  is not blinded. Therefore, 
an independent safet y monitoring board as described in the protocol of the core study  is not 
necessary .
10.2.4 Steering Committee
A steering committee (SC) may be established with experts in the field of CSU including 
investigators participating in the trial and Novartis representatives.
If established, the SC will ensure transparent management of the study  according to the protocol 
through recommending and approving modifications as circumstances require. The SC will 
review protocol amendments as appropriate. Together with the clinical trial team, the SC will 
also develop recommendations for publications of study results including authorship rules. The 
details of the role of the steering committee will be defined in the steering committee charter.
11 Data Collection and Database management
11.1 Data collection
Designated investigator staff will enter the data required by the protocol into the Electronic 
Case Report Forms (eCRF). The eCRFs have been built using fully validated secure web-
enabled software that conforms to 21 CFR Part 11 requirements, Investigator site staff will not 
be given access to the EDC system until they have been trained. Automatic validation programs 
check for data discrepancies in the eCRFs, allow modification and/or verification of the entered 
data b y the investigator staff.
The investigator/designee is responsible for assuring that the data (entered into eCRF) is 
complete, accurate, and that entry  and updates are performed in a timely  manner. The 
Investigator must certify  that the data entered are complete and accurate.
After final database lock, the investigator will receive copies of the subject data for archiving 
at the investigational site.
All data should be recorded, handled and stored in a way that allows its accurate reporting, 
interpretation and verification.
11.2 Database management and quality  control
Novartis personnel (or designated CRO) will review the data entered by investigational staff 
for completeness and accuracy . Electronic data queries stating the nature of the problem and 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system. Designated investigator site staff are required to 
respond promptly  to quer ies and to make an y necessary  changes to the data.
Concomitant treatments and prior medications entered into the database will be coded using the 
WHO Drug Reference List, which employ s the Anatomical Therapeutic Chemical classification 
system. Medical hist ory/current medical conditions and adverse events will be coded using the 
Medical dictionary  for regulatory  activities (MedDRA) terminology .

Novartis Confidential Page 63
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Laboratory  samples will be processed centrall y and the results will be sent electronicall y to 
Novartis.
ECG reading s will be processed centrally and results will be sent electronically  to Novartis.
Patients will fill in their eDiary  data on a device at home. The system will be supplied by a 
vendor, who will also manage the database. The database will be sent electronic ally to Novartis 
personnel.
Data about all study  treatment(s) dispensed to the subject and all dosage changes will be tracked 
using an Interactive Response Technology  (IRT). The system will be supplied by a vendor, who 
will also manage the database. The da ta will be sent electronically  to Novartis (or a designated 
CRO) at specific timelines.
Once all the necessary  actions have been completed and the database has been declared to be 
complete and accurate, it will be locked and made available for data analy sis. Any changes to 
the database after that time can onl y be made after written agreement b y Novartis development 
management.
11.3 Site monitoring
Before study  initiation, at a site initiation visit or at an investigator’s meeting, a 
Novartis/delegated CRO repre sentative will review the protocol and data capture requirements 
(i.e. electronic source (eSource) DDE or eCRFs) with the investigators and their staff. During 
the study , Novartis employ s several methods of ensuring protocol and GCP compliance and the 
quality/integrity  of the sites’ data. The field monitor will visit the site to check the completeness 
of subject records, the accuracy of data capture/data entry, the adherence to the protocol and to 
Good Clinical Practice, the progress of enrollment, and to ensure that study  treatment is being 
stored, dispensed, and accounted for according to specifications. Key study personnel must be 
available to assist the field monitor during these visits. Continuous remote monitoring of each 
site’s data may be performed by a centralized Novartis/delegated CRO/Clinical Research 
Associate (CRA) organization. Additionally , a central anal ytics organization may  anal yze data 
& identify  risks & trends for site operational parameters, and provide reports to Novartis clinical 
teams to assist with trial oversight.
The investigator must maintain source documents for each subject in the study , consisting of 
case and visit notes (hospital or clinic medical records) containing demographic and medical 
information, laboratory  data, ECGs, and the results of any other tests or assessments. All 
information on eCRFs must be traceable to these source documents in the subject’s file. The 
investigator must also keep the original ICF signed by the subject (a signed copy is given to the 
subject).
The investigator must give the monitor access to all relevant source documents to confirm their 
consistency  with the data capture and/or data entry . Novartis monitoring standards require full 
verification for the presence of informed consent, adherence to th e inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary  variables. Additional 
checks of the consistency  of the source data with the eCRFs are performed according to the 
study -specific monitoring plan. No informa tion in source documents about the identity  of the 
subjects will be disclosed.

Novartis Confidential Page 64
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
12 Data analy sis and statistical methods
12.1 Analysis sets
The Safety Analysis Set (SAF) includes all subjects who received at least one dose of study  
treatment during the treatment p eriod of this extension study .
For the observational period, the observational Full Analy sis Set (oFAS) includes all subjects 
who enrolled in the observational period.
All enrolled subjects includes all subjects who enrolled in this extension study .
12.2 Subject demographics and other baseline characteristics
Demographics and baseline characteristics
Demographic and baseline disease characteristics will be summarized for SAF and oFAS. 
Listing will be provided for all subjects enrolled.
Categorical data will be presented as frequencies and percentages. For continuous data, mean, 
standard deviation, lower quartile, median, upper quartile, minimum, and maximum will be 
presented.
Medical history
Relevant medical histories and current medical conditions before first dose of study  treatment 
in the treatment period will be summarized by s ystem organ class and preferred term according 
to MedDRA dictionary for SAF. Urticaria related medical history  will be summarized 
separately  for SAF.
All relevant medical histories and current medical conditions will be listed for all subjects 
enrolled. Cardiovascular history  and family  malignancy  history  for subjects developed 
malignancy  during the treatment period will be listed for SAF.

Novartis Confidential Page 65
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
12.3 Treatments
Study Treatment 
The duration of exposure (in weeks) will be summarized by means of descriptive statistics using 
the SAF. In addition, the number and percentage of subjects with exposure of at least certain 
thresholds (e.g. any exposure, >=1 week, >= 2 weeks, >= 3 weeks, >= 4 Weeks, ..., etc.) will 
be display ed.
Prior and Concomitant medication
Prior, 
non-urticaria related concomitant medications and urticaria related medication will be 
summarized separatel y by Anatomical Therapeutic Chemical (ATC) codes and main group for 
SAF.
Prior treatments are defined as treatment taken and stopped prior to first dose of study  treatment 
in the treatment period. Any treatment given at least once between the day of first dose of study 
treatment during treatment period and the last day of study  visitwill be a concomitant treatment, 
including those which were started prior to enter the treatment period.
In addition, prior and concomitant medical procedures and significant non
-drug therapies will 
be summarized by  primary  system organ class and MedDRA preferred term for SAF.
12.4 Analysis of the primary  endpoint(s)
The primary  analysis will focus on the safet y variables. The primary  safety  analysis will be 
analyzed using SAF.
12.4.1 Definition of primary  endpoint(s)
The primary  objective of this study  is to invest igate the long-term safety  and tolerability  of 
LOU064 in subjects with CSU.
The primary  variables are: AEs/SAEs, ECGs, laboratory  assessment, and vital signs, etc. 
Baseline for safet y analysis is defined as the last measurement before the first dose of study 
medication in the treatment period of this extension study .
Adverse events
All adverse events which newly start on the same day or after the first dose of study  medication 
in the treatment period of this extension study  OR get worsening on the same day or after the 
first dose of study  medication and within end of study  visit will be considered as treatment 
emergent adverse event for this extension study .
Number and percentage of subjects having any treatment emergent adverse events during the 
extension study , by system organ class and preferred term will be provided for:
All adverse events
Adverse events b y maximum severity
Drug related adverse events
Serious Adverse events
Adverse events leading to treatment discontinuation

Novartis Confidential Page 66
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Adverse events by standardized MedCRA Query  (SMQ) and preferred term will be provided.
Separate summaries will be provided for deaths, SAEs, and other significant AEs leading to 
discontinuation. For the definition of AEs and SAEs please see Section 10.1.1 and 
Section 10.1.2.
Laboratory data
Baseline is defined as last assessment (including unscheduled assessments) before the first dose 
day of treatment period.
Descriptive summary  statistics for laborato
ry data (hematology  and serum chemistry ) will be 
provided at baseline and post-baseline by test category , parameter, and visit during the treatment 
period.
Shift table on normal range between baseline and post baseline visits will be provided.
Number and percentage of patients with newl y occurring clinical notable laboratory  values (see 
Appendix 16.1 , Appendix 16.2 , and Appendix 16.3) will also be provided.
ECGs
Summary  statistics will be provided for ECG parameters b y visit during treatment period. Shift 
table on normal ranges and number and percentage of notable abnormalities will also be 
summarized.
Vital signs
Analy sis of the vital sign measurements using su mmary  statistics for the change from baseline 
for each post -baseline visit will be performed. Shifts with respect to normal ranges and number 
and percentage of notable abnormalities will also be summarized.
12.4.2 Statistical model, hypothesis, and method of analy sis
No hy pothesis testing is planned for the primary objective.
Summary  statistics for continuous variables will include N, mean, standard deviation, minimum, 
lower quartile, median, upper quartile, maximum.
Summary  statistics for discrete variables will be presented in contingency  tables and will 
include absolute and relative frequencies.
12.4.3 Handling of missing values/censoring/discontinuations
Not applicable.
12.4.4 Sensitivity and Supportive analy ses
Not applicable.

Novartis Confidential Page 70
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
results website and all required Health Authority  websites (e.g. Clinicaltrials.gov, EudraCT 
etc.) .
For details on the Novartis publication policy  including authorship criteria, please refer to the 
Novartis publication policy  training materials that were provided to you at the trial investigator 
meetings
13.4 Qualit y Control and Quality  Assurance
Novartis maintai ns a robust Quality  Management System (QMS) that includes all activities 
involved in quality  assurance and qualit y control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and I CH Guideline s.
Audits of investigator sites, vendors, and Novartis systems are performed by auditors, 
independent from those involved in conducting, monitoring or performing quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.
Audits are conducted to assess GCP compliance with global and local regulatory requirements, 
protocols and internal SOPs, and are performed according to written Novartis processes
14 Protocol adherence
This protocol defines the study  objectives, th e study procedures and the data to be collected on 
study  participants. Additional assessments required to ensure safety  of subjects should be 
administered as deemed necessary  on a case-by-case basis. Under no circumstances including 
incidental collection is an investigator allowed to collect additional data or conduct any 
additional procedures for any purpose involving any investigational drugs under the protocol, 
other than the purpose of the study . If despite this interdiction prohibition, data, informati on, 
observation would be incidentally  collected, the investigator shall immediately  disclose it to 
Novartis and not use it for any purpose other than the study , except for the appropriate 
monitoring on study  participants.
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study  this must be 
considered a protocol amendment, and unless such an amendment is agreed upon by 
Novartis and approved by theIRB/IEC and health authorities, where required, it cannot be 
implemented.
14.1 Protocol A mendments
Any change or addition to the protocol can onl y be made in a written protocol amendment that 
must be approved by Novartis, health authorities where required, andthe IRB/IEC prior to 
implementation.
Only  amendments that are required for subject safet y may be implemented immediately 
provided the health authorities are subsequently  notified by protocol amendment and the 
reviewing IRB/IEC is notified.
Notwithstanding the need for approval of formal protocol amendments, the investigator is 
expected to take any immediate action required for the safety  of any subject included in this 
study , even if this action represents a deviation from the protocol. In such cases, Novartis should 

Novartis Confidential Page 73
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
16 Appendices
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs
The following specific criteria have been identified for this stud y. Should these criteria be met, 
a re-test must be done within 5 days after the first assessment. Discontinuation of the study  
treatment should be considered if the abnormal hematology  parameter is confirmed:
Hemoglobin: < 10 g/dl
Platelets: < 75 000/mm3
White blood cells: < 3 000/mm3
Neutrophils: < 1 500/mm3
For all other laboratory  assessments, the central laboratory  will flag laboratory  values falling 
outside of the normal ranges on the central laboratory  report (which the investigator should 
review and sign-off) and the investigator will report any values considered clinically  significant 
in the eCRF.
Notabl e values for vital signs and change from baseline will be summarized. 
Notable values are defined as follows: heart rate of < 50 and > 100 bpm; systolic blood pressure 
of < 90 and ≥ 140 mmHg; diastolic blood pressure of < 60 and ≥ 90 mmHg.
For ECGs a notab le QTc value is defined as a QTc (Fridericia’s) interval of greater than 450 
msec for males or greater than 460 msec for females –all such ECGs will be flagged by the 
central CRO’s cardiologist and require assessment for clinical relevance b y the investig ator. 

Novartis Confidential Page 74
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
16.2 Appendix 2: Liver event and Laboratory  trigger Definitions and 
Follow -up Requirements
Table 16-1 Liver Event and Laboratory  Trigger Definitions
Definition/ thresho ld
LIVER LABORATORY 
TRIGGERS3 x ULN < ALT / AST ≤ 5 x ULN
1.5 x ULN < TBL ≤2 x ULN
LIVER EVENTS -ALT or AST > 5 × ULN
-ALP > 2 × ULN (in the absence of known bone pathology)
-TBL > 2 × ULN (in the absence of known Gilbert syndrome)
-ALT or AST > 3 × ULN and INR > 1.5
-Potential H y’s Law cases (defined as ALT or AST > 3 × ULN and TBL > 
2 × ULN [m ainly conjugated fraction] without notable increase in ALP to 
> 2 × ULN)
-Any clinical event of jaundice (or equivalent term)
-ALT or AST > 3 × ULN accompanied by (general) malaise, fatigue, 
abdom inal pain, nausea, or vomiting, or rash with eosinophilia
-Any adverse event potentially indicative of a liver toxicity*
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; the non -infectious hepatitis; the benign, malignant and unspecified liver 
neoplasms TBL: total bilirubin; ULN: upper limit of normal
Table 16-2 Follo w Up Requirements for Liver Events and Laboratory  Triggers
Criteria Actions required Follow -up monitoring
Potential Hy’s Law 
casea-Discontinue the study treatment immediately
-Hospitalize, if clinically appropriate
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, 
Alb,PT/INR, ALP and GGT 
until resolutionc(frequency 
atinvestigator discretion)
ALT or A ST
> 8 × ULN -Discontinue the st udy treatment immediately
-Hospitalize, if clinically appropriate
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, 
Alb,PT/INR, ALP and GGT 
until resolutionc(frequency 
at investigator discretion)
> 3 × ULN and INR 
> 1.5-Discontinue the study treatment immediately
-Hospitalize, if clinically appropriate
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, me dical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, 
Alb,PT/INR, ALP and GGT 
until resolutionc(frequency 
at investigator discretion)

Novartis Confidential Page 75
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Criteria Actions required Follow -up monitoring
> 5 to ≤ 8 × ULN -Repeat LFT within 48 hours
-If elevation persists, continue follow -up 
monitoring
-If elevation persists for more than 2 weeks, 
discontinue the study drug
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, 
Alb,PT/INR, ALP and GGT 
until resolutionc(frequency 
at investigator discretion)
> 3 × ULN 
accompanied by 
symptomsb-Discontinue the study treatment immediately
-Hospitalize, if clinically appropriate
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, 
Alb,PT/INR, ALP and GGT 
until resolutionc(frequency 
at investigator discretion)
> 3 to ≤ 5 × ULN 
(patient is 
asymptomatic)-Repeat LFT within the next week
-If elevati on is confirmed, initiate close 
observation of the subjectInvestigator discretion
Monitor LFT within 1 to 4 
weeks
ALP (isolated)
> 2 × ULN (in the 
absence of known 
bone pathology)-Repeat LFT within 48 hours
-If elevation persists, establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
TBL (isolated)
> 2 × ULN (in the 
absence of known
Gilbert syndrome)-Repeat LFT within 48 hours
-If elevation persists, discontinue the study 
drug immediately
-Hospitalize if clinically appropriate
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, 
Alb,PT/INR, ALP and GGT 
until resolutionc(frequency 
atinvestigator discretion)
Test for hemoly sis 
(e.g., reticulocytes, 
haptoglobin, unconjugated 
[indirect] bilirubin)
> 1.5 to ≤ 2 × ULN 
(patien t is 
asymptomatic)-Repeat LFT within the next week
-If elevation is confirmed, initiate close 
observation of the subjectInvestigator discretion
Monitor LFT within 1 to 4 
weeks or at next visit
Jaundice -Discontinue the study treatment immediately
-Hospitalize the patient
-Establish causality
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRFALT, AST, TBL, Alb, 
PT/INR, ALP and GGT until 
resolutionc(frequency at 
investigato r discretion)
Any AE potentially 
indicative of a liver 
toxicity*-Consider study treatment interruption or 
discontinuation
-Hospitalization if clinically appropriate
-Establish causalityInvestigator discretion

Novartis Confidential Page 76
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
Criteria Actions required Follow -up monitoring
-Record the AE and contributing factors (e.g. 
concomitant medication, medical history, 
laboratory values) in the appropriate eCRF
aElevated ALT/AST > 3 × ULN and TBL > 2 × ULN but without notable increase in ALP to > 2 × ULN 
b(General) malaise, fatigue, abdominal pain, nausea, or vomiting, or rash wi th eosinophilia 
cResolution is defined as an outcome of one of the following: (1) return to baseline values, (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level after 
a maximum of 6 months, (4) liver transplantation, and (5) death.
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage -
related conditions; non -infectious hepatitis; the benign, malignant and unspecified liver neoplasms.
Based on investigator ’s discretion, investigation(s) for contributing factors for the liver event 
can include: serology  tests, imaging and pathology  assessments, hepatologist’s consultancy , 
obtaining more detailed history  of symptoms and prior or concurrent diseases, history  of 
concomitant drug use, exclusion of underl ying liver disease.

Novartis Confidential Page 77
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
16.3 Appendix 3: Specific Renal A lert Criteria and A ctions and Event 
Follow -up
Table 16-3 Specific renal alert criteria and actions
Renal A lert Actions
Confirmed serum creatinine increase 25 –49% 
[Canada only ] Consider causes and possible interventions
Follow up within 2 -5 days; increase fluid 
intake before assessment if appropriate
Repeat follow -up (every 2 -5 days) until 
creatinine is <125% of baseline value
Serum creatinine increase ≥50 % 1             
[Canada only ]Consider causes and possible interventions 
and initiate renal investigation
Repeat assessment within 24 -48h if possible
Interruption of study  drug, close follow -up 
(ever y 24-48 h), consider patient 
hospitalization and specialized treatment 
until creatinine is <125% of baseline value
Confirmed serum creatinine increase 25 –49% Consider causes and possible interventions
Follow up within 2 -5 days
Serum creatinine increase ≥50 % 1Consider causes and possible interventions
Repeat assessment within 24 -48h if possible
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
Consider patient hospitalization and 
specialized treatment
New onset dipstick proteinuria ≥ 3+
When urine proteins are measured as a follow -
up of positive urine dipstick measurements:
Protein -creatinine ratio (PCR) ≥ 1g/g Cr (or 
mg/mmol equivalent as converted by the 
measuring laborator y)Consider causes and possible interventions
Assess serum albumin & serum total protein
Repeat assessment to confirm
Consider drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected
New onset hematuria ≥ 3+ on urine dipstick Assess & document
Repeat assessment to confirm
Distinguish hemoglobinuria from hematuria
Urine sediment microscopy
Assess sCr
Exclude infection, trauma, bleeding from the 
distal urinary tract/bladder, menstruation
Consider bleeding disorder
1 Corresponds to KDIGO criteria for Acute Kidney Injury
Additional specialized assessments are available to assess renal function or renal pathology . 
(Note: in exceptional cases, when a nephrologist considers a renal biops y, it is recommended 

Novartis Confidential Page 78
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
to make slide specimen available for evaluation by the Renal Safet y Group to potentially  
identify  project -wide patterns of nephrotoxicity .)
Whenever a renal event is identified, a detailed patient history and examination are indicated to 
identify  and potentiall y eliminate risk factors that may have initiated or contributed to the event:
Blood pressure assessment (after 5 -minute rest, with an appropriate cuff size)
Signs and s ymptoms like fever, headache, shortness of breath, back or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema
Changes in blood pressure, body  weight, fluid intake, voiding pattern, or urine output
Concomitant events or procedures such as trauma, surgical procedures, cardiac or hepatic 
failure, contrast media or other known nephrotoxin administra tion, or other diseases or 
causes, e.g., deh ydration due to delirium, tumor lysis
Table 16-4 Renal event follo w-up
FOLLOW -UP OF REN AL EVENTS
Assess, document and record in CRF
Urine dipstick and sediment microscopy evidence of Drug -Induced Nephrotoxicity 
(DIN): crystals, red blood cells (dysmorphic/glomerular vs. non -dysmorphic/non -glomerular), 
white blood cells, tubular epithelial cells
Blood pressure and body weight
Serum creatinine, BUN, electrolytes (sodium, potassium, phosphate, calcium), bicarbonate and 
uric acid
Urine output
Review and record possible contributing factors to the renal event (co -medications, other co- morbid 
conditions) and additional diagnostic procedures (MRI etc.) in the CRF
Monitor patient regularly (frequency at investigator’s discretion) until
Event resolution: (sCr within 10% of baseline or PCR < 1 g/g Cr, or ACR <300 mg/g Cr) or
Event stabilization: sCr level with ±10% variability over la st 6 months or protein -creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.
Analysis of urine markers in samples collected over the course of the DIN event

Novartis Confidential Page 79
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
16.4 Appendix 4: Prohibited medications
The lists provided in the table below are non-exhaustive. In case of any doubt, the corresponding 
SmPC should be checked.
Table 16-5 Moderate and strong inhibitors of CYP3A 4
Strong inhibitors of 
CYP3A4boceprevir, clarithrom ycin, cobicistat, conivaptan, 
danoprevir/ritonavir,darunavir/ritonavir, elvitegravir/ritonavir, grapefruit juice, 
idelalisib,indinavir, indinavir/ritonavir, itraconazole, ketoconazole, 
LCL161,lopinavir/ritonavir, mibefradil, nefazo done, nelfinavir, 
posaconazole,ritonavir, saquinavir, saquinavir/ritonavir, telaprevir, 
telithrom ycin,tipranavir/ritonavir,troleandom ycin, Viekira pack, voriconazole
Moderate inhibitors 
of CYP3A4ACT-178882, amprenavir, aprepitant, atazanavir, casopitant,
cimetidine,ciprofloxacin, crizotinib, c yclosporine, darunavir, diltiazem, 
dronedarone,er ythrom ycin, faldaprevir, ferula asafetida resin (herbal 
product), FK1706,fluconazole, imatinib, isavuconazole, netupitant, nilotinib, 
schisandra,sphenanthera, tofisopa m, verapamil
Table 16-6 Moderate and strong inducers of CYP3A 4
Strong inducers of 
CYP3A4avasimibe, carbamazepine, enzalutamide, ifampin, mitotane, 
phenobarbital,phenytoin, rifabutin, St. John’s wort (herbal product)
Moderate inducers of 
CYP3A4bosentan, efavirenz, etravirine, lersivirine, lopinavir, modafinil, 
nafcillin,ritonavir/tipranavir, semagacestat, talviraline, thioridazine

Novartis Confidential Page 80
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1

Novartis Confidential Page 81
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1

Novartis Confidential Page 82
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1

Novartis Confidential Page 83
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1

Novartis Confidential Page 84
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1

Novartis Confidential Page 85
Amended Protocol Version v03 Clean Protocol No. CLOU064A2201E1
